Home › Compare › EWGFF vs ABBV
EWGFF yields 5714.29% · ABBV yields 3.06%● Live data
📍 EWGFF pulled ahead of the other in Year 1
Combined, EWGFF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of EWGFF + ABBV for your $10,000?
Eat Well Investment Group Inc. is a venture capital firm specializing in early-stage, seed and emerging growth investments. The firm seeks to invest at various stages of development, including pre-initial public offering, and/or early stage companies requiring start-up or development capital. The firm seeks to invest in agribusiness, food-tech, consumer packaged goods (CPG), plant-based and ESG (environmental, social and governance) sectors. The firm also seeks to invest in marketable securities comprising common shares and other equity instruments of companies in the mining, oil and gas, media technology, and medical technology industries that are listed on various Canadian stock exchanges or the OTCBB in the United States. It considers to invest over a number of sectors, including but not limited to: precision fermentation, regenerative agriculture, fintech, healthcare, the resource sector, information and communications technology, and energy & clean technology. It typically invests in Canada and the United States. The firm seeks to invest between $0.25 million to $2 million. The firm is also involved in assisting financing, identifying acquisition targets, developing strategic plans, supporting operations, and implementing exit strategies. The firm also works with co-investors. Eat Well Investment Group Inc. was founded in 2007 and is based in Vancouver, Canada.
Full EWGFF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.